Navigation Links
MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
Date:9/16/2008

es. We are also continuing our preparations to submit a new drug application by year-end or shortly thereafter."

About Study 009

The primary objective of this trial was to compare the efficacy (as expressed by the change in A1C levels) of the treatment received by the TI group versus the treatment received by the comparator group. A total of 565 patients were studied in sites in the United States, Europe and Latin America. A total of 293 patients received Technosphere Insulin, and 272 patients received insulin aspart.

Over the 52-week period of this study, A1C levels decreased comparably in the two treatment groups, with a between-group difference of -0.24%. The 95% confidence interval (-0.09% to -0.40%) did not exceed the predetermined threshold of 0.40%, thereby establishing non-inferiority between Technosphere Insulin and insulin aspart. There were no interactions associated with the data from different sites or different countries; the statistical analysis was conducted on the entire intention-to-treat (ITT) population.

A comparable percentage of patients reached A1C target levels between the two treatment groups. There were no statistically significant differences in the percentage of patients whose A1C level decreased below 8.0% (50.7% for the TI group; 56.3% for the comparator group); 7.0% (16.3%, TI group; 16.2%, comparator group); and 6.5% (7.4%, TI group; 7.2%, comparator group).

Over the 52-week period of the study, fasting blood glucose (FBG) levels decreased significantly (p<0.01) in the TI group compared to the FBG levels observed in patients using insulin aspart. Among patients using TI, mean FBG decreased by 48.8 mg/dL from 188.6 mg/dL at screening to 139.8 mg/dL at the end of the treatment period, compared to a drop of only 20.2 mg/dL from 180.3 mg/dL to 160.1 mg/dL over the same period in the comparator group.

Patients in the TI group lost an average of 2.0 kg (4.3 pounds) over the 52-week treatment period
'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. MannKind Addresses Pfizers Announcement Regarding Exubera
2. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
3. Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate
4. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
5. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
6. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
7. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
8. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
9. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
10. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
11. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... 16 RealMed has been ranked ... the 2009 Top 20 Best in ... report. RealMed is a dynamic revenue cycle ... processing between healthcare providers and all ... firm specializing in vendor performance measurement in ...
(Date:12/16/2009)... to Millennium Research Group (MRG), the global authority ... in China supported rapid expansion of the Chinese ... to fuel growth in the coming years. ... Cardiology Devices 2010 report finds that initiatives ... Chinese drug-eluting stent market to reach a value ...
(Date:12/16/2009)... -- Biovista Inc.,today announced that it was awarded ... the 2009 New England Venture Summit, held on ... cutting edge private companies,driving the future of innovation, ... other privately held companies that play a leading ... Clean-tech sectors. , "We ...
Breaking Medicine Technology:RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 2Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 3Biovista Inc. Named Top Innovator in Life Sciences 2Facet Biotech and Trubion Announce Worldwide Collaboration for the Development and Commercialization of TRU 016 55596 1Facet Biotech and Trubion Announce Worldwide Collaboration for the Development and Commercialization of TRU 016 55596 2Facet Biotech and Trubion Announce Worldwide Collaboration for the Development and Commercialization of TRU 016 55596 3Facet Biotech and Trubion Announce Worldwide Collaboration for the Development and Commercialization of TRU 016 55596 4Facet Biotech and Trubion Announce Worldwide Collaboration for the Development and Commercialization of TRU 016 55596 5Facet Biotech and Trubion Announce Worldwide Collaboration for the Development and Commercialization of TRU 016 55596 6Fast Food Choices for iPhone 28TM 29 iPod 28R 29 Touch Users With Celiac Coeliac 26 Food Allergies 55593 1Fast Food Choices for iPhone 28TM 29 iPod 28R 29 Touch Users With Celiac Coeliac 26 Food Allergies 55593 2Haven Healthcare of Utah Receives Award for Quality Care Fourth Year in a Row 55588 1Haven Healthcare of Utah Receives Award for Quality Care Fourth Year in a Row 55588 2
... ... Annually, CAMBRIDGE, Mass., Aug. 2 ... trial of Mozobil(TM),(plerixafor) has successfully met its primary and secondary endpoints,demonstrating positive ... non-Hodgkin,s lymphoma. The combined strength of these two trials -- in ...
... KING OF PRUSSIA, Pa., Aug. 2 ... experiments with its small-molecule,MIF inhibitors showed oral ... the Company announced that it is advancing ... Macrophage Migration Inhibitory Factor, or MIF, is ...
Other Medicine Technology:Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint 2Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint 3Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint 4Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint 5Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint 6Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint 7Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors 2
(Date:12/17/2009)... last few weeks there has been an increase of ... e cigarette opposition in an attempt to scare the ... tactics of these groups when the evidence clearly shows ... tobacco according to several studies, lab reports and opinions ... world. ,, Special interest groups appear to have ...
(Date:12/17/2009)... Calif., Dec. 17 Abaxis, Inc. (Nasdaq: ... point-of-care blood analysis instruments and rapid tests for ... that it has entered the production animal diagnostics ... Influenza Antigen Test. This is a USDA-licensed test ... chickens, turkeys and ducks. The disposable, non-instrumented device, ...
(Date:12/17/2009)... LONDON, December 17 Researchers from the ... Loughborough University in the UK are today,encouraging ... in the,New Year following concerning research* that shows ... together as a family (68%), with the,Portuguese being ... likely to,walk together. , ...
(Date:12/17/2009)... functions were determining factors. StaffKnex, developers of web-based nurse ... selected by Lifespace Communities to deliver its software solution ... ... Cleveland, OH (PRWEB) December 17, ... nurse scheduling and employee communication software, recently announced it ...
(Date:12/17/2009)... engines like Google Local and in front of their local customers ... Registration service offered by New Orleans based Webtyde Internet Marketing. ... ... In order to be competitive locally and nationally, businesses must have ... local map section in a major search engine, a business must ...
Breaking Medicine News(10 mins):Health News:Special Interest Deceptions Continue to Rampant About Electronic Cigarettes 2Health News:ABAXIS(R) Announces Exclusive Worldwide OEM Agreement for a Lateral Flow Avian Influenza Antigen Test Kit 2Health News:ABAXIS(R) Announces Exclusive Worldwide OEM Agreement for a Lateral Flow Avian Influenza Antigen Test Kit 3Health News:ABAXIS(R) Announces Exclusive Worldwide OEM Agreement for a Lateral Flow Avian Influenza Antigen Test Kit 4Health News:The Family Walk - a Dying Tradition Around the World? 2Health News:Lifespace Communities Selects StaffKnex Software for Nurse Scheduling and Employee Communications 2Health News:Lifespace Communities Selects StaffKnex Software for Nurse Scheduling and Employee Communications 3Health News:New Orleans Based Internet Marketing Is Helping Small Businesses Get a Chance to Shine On the Web 2
... that evening administration of the central alpha(2)-agonists guanabenz ... the morning in hypertensive patients. The study was ... receive once-daily evening administration of guanabenz or clonidine ... of the two drugs in the morning and ...
... lifestyle with limiting TV time could prevent obesity and type ... watching results in a lower metabolic rate when compared to ... a car. Prolonged TV watching is also linked to obesity ... and hardly concentrate on reducing sedentary behaviours.// ...
... that treatment with adult stem cells has cured mice ... have recovered completely from paralysis of their back legs, ... with stem cells extracted from the brains of adult ... showed that the stem cells had migrated to and ...
... in Journal of the American College of Cardiology suggests ... profile for the heart when delivered through a patch ... the largest study of its kind, was cut short ... Replacement Therapy (a combination of estrogen and progestin) increased ...
... glucose levels are above normal. People with diabetes have ... into a sugar called glucose, which is carried by ... the hormone insulin, made in the pancreas, to help ... can prevent or delay complications by keeping blood glucose ...
... discuss with their physicians, can be an early warning ... disease, hypertension, diabetes, high cholesterol, obesity and smoking are ... estimated that Erectile dysfunction affects 40 million men, yet ... tell and doctors never ask.// ED is one symptom ...
Other Medicine News:
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: